350
Participants
Start Date
May 18, 2015
Primary Completion Date
February 23, 2016
Study Completion Date
January 2, 2018
Secukinumab
Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
Secukinumab
Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
Placebo
Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
Novartis Investigative Site, Vienna
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Fribourg
Novartis Investigative Site, Frederiksberg
Novartis Investigative Site, Kongsvinger
Novartis Investigative Site, Kogarah
Novartis Investigative Site, Malvern East
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Maroochydore
Novartis Investigative Site, Pleven
Novartis Investigative Site, Hobart
Novartis Investigative Site, Targovishte
Novartis Investigative Site, Graz
Novartis Investigative Site, Torino
Novartis Investigative Site, Berlin
Novartis Investigative Site, Athens
Novartis Investigative Site, Berlin
Novartis Investigative Site, Córdoba
Novartis Investigative Site, A Coruña
Novartis Investigative Site, Santiago de Compostela
Novartis Investigative Site, Genova
Novartis Investigative Site, Duncansville
Novartis Investigative Site, Athens
Novartis Investigative Site, Bad Doberan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Pátrai
Novartis Investigative Site, Madrid
Novartis Investigative Site, Columbia
Novartis Investigative Site, Aventura
Novartis Investigative Site, Göttingen
Novartis Investigative Site, Verona
Novartis Investigative Site, Santander
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Herne
Novartis Investigative Site, Barakaldo
Novartis Investigative Site, Peoria
Novartis Investigative Site, Lincoln
Novartis Investigative Site, Shreveport
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Mesquite
Novartis Investigative Site, München
Novartis Investigative Site, Germering
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Upland
Novartis Investigative Site, Topoľčany
Novartis Investigative Site, Partizánske
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Seattle
Novartis Investigative Site, S.-Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Kemerovo
Novartis Investigative Site, Barnaul
Novartis Investigative Site, Barnaul
Novartis Investigative Site, Anniston
Novartis Investigative Site, Voorhees Township
Novartis Investigative Site, Vienna
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, Pointe-Claire
Novartis Investigative Site, Trois-Rivières
Novartis Investigative Site, Ostrava
Novartis Investigative Site, Prague
Novartis Investigative Site, Prague
Novartis Investigative Site, Uherské Hradiště
Novartis Investigative Site, Odense
Novartis Investigative Site, Hyvinkää
Novartis Investigative Site, Jyväskylä
Novartis Investigative Site, Chemnitz
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Heerlen
Novartis Investigative Site, Leiden
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Bialystok
Novartis Investigative Site, Elblag
Novartis Investigative Site, Poznan
Novartis Investigative Site, Poznan
Novartis Investigative Site, Poznan
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Piešťany
Novartis Investigative Site, Sabinov
Novartis Investigative Site, Stará Ľubovňa
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, Leytonstone
Novartis Investigative Site, Doncaster
Novartis Investigative Site, Wolverhampton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY